DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for childhood absence epilepsy — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChildhood absence epilepsy maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for childhood absence epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
VRK serine/threonine kinase 2 (VRK2) — VRK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sindrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2V62 · 1.7 Å · ligand SUCCINIC ACID (SIN). Experimental structure, not a prediction.
What the evidence adds up to
In childhood absence epilepsy, roughly two thirds of children can be expected to enter long-term remission, while the remaining third do not respond to available antiseizure medications. Those medications often produce serious side effects and can worsen symptoms in some patients. Psychosocial outcome is often poor even for patients whose epilepsy remits; remission does not prevent psychosocial morbidity. Early-onset pure absence epilepsy, a distinct syndrome with onset between a few months and four years of age, shows good seizure control with antiepileptic drugs and normal intellectual outcome.
The molecular mechanisms that generate absence seizures are complex and multifactorial, varying with different genetic backgrounds. Aberrant neuronal activity may arise from several incompletely understood mechanisms. Despite advances in cutting-edge technologies, dissecting the causal factors that could be targeted for precision medicines without side effects remains a high priority and the ultimate goal. The genetic abnormalities and pathophysiological mechanisms of childhood absence epilepsy are still not fully understood.
In five consanguineous Tunisian families with at least two siblings meeting diagnostic criteria for childhood absence epilepsy, linkage analyses and direct sequencing excluded the genes CACNG2, CACNA1A, CACNB4, and CACNA2D2—orthologs of genes responsible for autosomal recessive absence seizures in mice. These families are expected to help identify the responsible gene or genes, but no causative gene has yet been reported from that work.
What is still missing is a clear identification of the specific genetic and molecular targets that could be exploited for treatment, particularly for the one third of patients who are refractory to current drugs. Adequately powered, genetically stratified clinical trials are lacking, as is funding for the basic science needed to translate findings from animal models and family studies into patient-specific therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2003 · 56 citations · open access
Natural History of Absence Epilepsy in Children
AbstractAbsence seizures may be seen in a variety of epileptic syndromes in childhood. Identification of the specific syndrome is important to determine medical prognosis. With childhood absence epilepsy, approximately two thirds of children can be expected to enter long-term remission, while in juvenile absence epilepsy, seizure control is often achieved, however, lifelong treatment is usually required. Other absence syndromes have a poorer prognosis, with lower rates of seizure control and remission. Psychosocial outcome is often poor, even in patients with more benign forms of absence epilepsy. Remission of epilepsy does not preclude psychosocial morbidity.
Early‐onset pure absence epilepsy: a distinct epileptic syndrome
AbstractUNLABELLED: Early-onset pure absence epilepsy has not yet considered in the International League Against Epilepsy classification, but several reports have supported its existence as a distinct epileptic syndrome primarily manifesting with typical absences in early childhood. This review summarizes the current understanding on this epilepsy. CONCLUSIONS: Early-onset pure absence epilepsy is a distinct epilepsy characterized by absences starting from a few months to 4 years of age, normal early psychomotor development, good antiepileptic drug seizure control and normal intellectual outcome.
International Journal of Molecular Sciences · 2024 · 10 citations · open access
Molecular Mechanisms Underlying the Generation of Absence Seizures: Identification of Potential Targets for Therapeutic Intervention
AbstractUnderstanding the molecular mechanisms underlying the generation of absence seizures is crucial for developing effective, patient-specific treatments for childhood absence epilepsy (CAE). Currently, one-third of patients remain refractive to the antiseizure medications (ASMs), previously called antiepileptic drugs (AEDs), available to treat CAE. Additionally, these ASMs often produce serious side effects and can even exacerbate symptoms in some patients. Determining the precise cellular and molecular mechanisms directly responsible for causing this type of epilepsy has proven challenging as they appear to be complex and multifactorial in patients with different genetic backgrounds. Aberrant neuronal activity in CAE may be caused by several mechanisms that are not fully understood. Thus, dissecting the causal factors that could be targeted in the development of precision medicines without side effects remains a high priority and the ultimate goal in this field of epilepsy research. The aim of this review is to highlight our current understanding of potential causative mechanisms for absence seizure generation, based on the latest research using cutting-edge technologies. This information will be important for identifying potential targets for future therapeutic intervention.
Familial form of typical childhood absence epilepsy in a consanguineous context
AbstractCausative genes for childhood absence epilepsy (CAE) are unknown partly because families are small or phenotypically heterogeneous. In five consanguineous Tunisian families with at least two sibs with CAE, 14 patients fulfilled the diagnostic criteria for CAE (Epilepsia 1989; 30:389-399). Linkage analyses or direct sequencing excluded CACNG2, CACNA1A, CACNB4, and CACNA2D2, orthologs of genes responsible for autosomal recessive (AR) absence seizures in mice. These families will help identify (a) gene(s) responsible for CAE.
AbstractChildhood absence epilepsy is an idiopathic, generalized non-convulsive epilepsy with a multifactorial genetic aetiology. While molecular-genetic analyses of affected human families have led to important breakthroughs in the identification of candidate genes for the simple mendelian types of idiopathic generalized epilepsies, the genetic abnormalities and the pathophysiological mechanisms of childhood absence epilepsy are still not fully understood.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
